INTRODUCTION
============

Non-nutritive sweeteners (NNS) were first introduced as early as 1878 as replacements for standard table sugar.[@ref1] NNS are characterized by providing few to no calories, whereas nutritive sweeteners (NS), such as standard table sugar, contain a caloric load. Both NNS and NS contribute to the flavor and texture of foods, primarily sweet taste. NNS are, however, significantly sweeter than NS, by as many thousands of times. Due to their extraordinary sweetness, much less of the substance is added to foods by consumers, thus reducing caloric intake.[@ref2] Obese and diabetic individuals use NNS to reduce caloric and carbohydrate intake for weight management, as well as for glycemic control.[@ref1] NNS are derived from either chemical or natural sources. For instance, aspartame, acesulfame potassium, and sucralose are derived from chemical sources, while stevia and its extract stevioside come from natural sources.

The global market for NNS grew 5.1% annually between 2008 and 2015.[@ref3] Consumption of NNS sweetened beverages by American adults increased from 21.1% in 2003--2004 to 24.9% in 2009--2010. In Korea, while NNS consumption is well below acceptable daily intake levels, there is some evidence to suggest that there may be a trend towards reduced intake in recent years.[@ref4] Commercial NNS that have been approved by the United States Food and Drug Administration are listed in [Table 1](#T1){ref-type="table"}. During the same time span, consumption by children jumped from 7.8% to 18.9%.[@ref5] NNS consumption has become increasingly popular among women and children in particular.[@ref6] The exact reasons that NNS use has grown in these demographics is unknown, although speculations can be made. Women are more likely to attempt weight loss,[@ref7] and are therefore likely to selectively choose products labeled as "no sugar," "diet," or "reduced sugar" that contain NNS instead of standard table sugar (sucrose). While NNS-sweetened beverage consumption has increased in adults regardless of degree of adiposity, only normal weight children showed increases.[@ref8]

Obesity is linked to many adverse health outcomes, including higher risks of developing diabetes and cardiovascular disease. Obesity is no longer only a concern in Western countries, but in Asian countries as well. The Korean Society for the Study of Obesity reports a steadily increasing rate of obesity, from 29.7% in 2009 to 32.4% in 2015.[@ref9] The associated national health care expenditure is \$1.8 billion.[@ref9] While sucrose does not directly cause diabetes, it has been linked to negative impacts on glucose tolerance in healthy individuals.[@ref10] Diets high in sucrose have also been shown to cause weight gain and obesity, which can lead to the development of diabetes.[@ref11] Large visceral fat stores cause fat cells to release proinflammatory cytokines. This puts the body into an inflammatory state, which can make insulin responsive cells insensitive to the presence of insulin.[@ref12] Compounding the insensitivity brought on by inflammation, adipose tissue may release fat molecules into the blood, which may in turn lead to additional reduced insulin sensitivity.[@ref13]

Diabetes mellitus is a chronic metabolic disease that disrupts the hormonal networks responsible for stabilizing blood glucose levels through the absolute or relative hindrance of insulin secretion and/ or deficits in insulin resistance. Diabetes is a growing worldwide epidemic. In the United States alone, 30.3 million individuals, or 9.4% of the population, have diabetes. Furthermore, a staggering 84.1 million Americans have prediabetes, placing them at immediate risk of developing diabetes.[@ref14] Type 2 diabetes is characterized by a combination of β-cell dysfunction and a resistance to insulin that is released.[@ref15] Diabetes represents a significant financial burden on healthcare systems, as it accounts for more than 10% of total healthcare spending in the United States, Canada, and Europe.[@ref16] This burden is likely to increase even more in the coming years.

Research has brought the efficacy of using NNS to ameliorate or prevent metabolic diseases into scrutiny. Despite widespread usage, their supposed benefits have yet to be verified. In fact, some evidence suggests that NNS are associated with metabolic disease, particularly obesity. Since NNS have zero to very minor caloric load, they cannot contribute directly to obesity, but instead may influence metabolic processes. Research has uncovered multiple mechanisms that may play roles in how NNS could trigger metabolic disease.[@ref1]

ARTICLE SEARCH
==============

Two electronic databases (PubMed and Google Scholar) were searched for articles containing the keywords "non-nutritive sweeteners," "artificial sweeteners," "sugar substitutes," "stevia," "aspartame," "sucralose," "acesulfame potassium," "neotame," "saccharin," "diabetes," "metabolic disease," and "obesity." The search was limited to articles published in the English language from January 2008 to January 2019.

PROSPECTIVE COHORT STUDIES OF NNS USE AND OBESITY
=================================================

As shown in [Table 2](#T2){ref-type="table"}, one meta-analysis examining nine prospective cohort studies reported no significant association between NNS consumption and body weight or fat mass but did report significant links to body mass index (0.03 kg/m^2^; 95% confidence interval \[CI\], 0.01--0.06 kg/m^2^).[@ref17] Similar modest increases in body mass index were reported by another meta-analysis (0.05 kg/m^2^; 95% CI, 0.03-- 0.06 kg/m^2^) of 30 prospective cohort studies.[@ref18] That study reported that individuals with higher NNS consumption had increased risks for metabolic syndrome, obesity classification, cardiovascular events, and diabetes.[@ref18]

A more recent meta-analysis showed similar results.[@ref19] This study obtained its data from 35 observational studies. Data from multiple studies, with a combined population of 17,934, showed that compared to higher doses of NNS, lower doses were associated with reduced weight gain (−0.09 kg; 95% CI, −0.13 to −0.05 kg). These results remained true in individuals who both were and were not actively trying to lose weight.

Another study utilized Framingham Heart Study data to compare regular versus diet soft drink consumption and determine risk for metabolic disease.[@ref20] The results of this analysis demonstrated that participants who consumed greater amounts of soda, whether diet or regular, had increased likelihood of showing signs of metabolic syndrome. Furthermore, NNS-sweetened diet drinks were equally associated with metabolic syndrome as regular drinks. These results were like those found in comparable studies.[@ref21] This evidence suggests that NNS use may not prevent metabolic syndrome, but rather have comparable effects to NS.

RANDOMIZED, CONTROLLED TRIALS OF NNS USE AND OBESITY
====================================================

One key review of NNS effect on weight management by Rogers et al.[@ref22] utilized multiple meta-analyses of randomized, controlled trials to demonstrate potential benefits or neutral effects on obesity. Among animal studies, 62 of 90 reported decreased or equal body weight after NNS consumption. Of the 28 studies that reported weight gain, 19 used the same learning design.[@ref22] In the studies with this learning design, rats were intermittently exposed to an NNS sweetened diet, rotated with the same diet without added sweetener.[@ref23][@ref24]-[@ref25] These 19 studies demonstrate concepts related to alterations in sweet taste receptors better than a link to weight gain.

To add further insights, the Rogers et al.[@ref22] study included a second meta-analysis examining short term randomized, controlled trials that compared NNS against sugar-sweetened items before an ad libitum meal. NNS were associated with reduced total energy intake (--94 kcal; 95% CI, --122 to --66 kcal). No difference between NNS and unsweetened waters were found (--2 kcal; 95% CI, --30 to 26 kcal). In addition, the study included a meta-analysis of longer-term (4 weeks to 40 months) randomized controlled trials, which reported reductions of body weight with NNS interventions (--1.35 kg; 95% CI, --2.28 to --0.42 kg).[@ref22] A similar reduction in body weight was found when NNS interventions were compared to unsweetened water (--1.24 kg; 95% CI, --2.[@ref22] to --0.26 kg). Other studies reported similar findings. Randomized, controlled trials of NNS show reversal or inhibition of weight gain.[@ref17],[@ref18] These data points are corroborated by a meta-analysis by Toews et al.[@ref19], which looked at two randomized, controlled trials, with a combined population of 174. This showed a minor beneficial effect of NNS on body mass index (−0.6; 95% CI, −1.19 to −0.01). Another metaanalysis by Wiebe et al.,[@ref25] looked at differences in energy intake caused by NNS use. This meta-analysis found two randomized, controlled trials that compared energy intake between a sucrose group and an NNS group. The results showed a 250−500 kcal reduction in the NNS group (95% CI, 153−806 kcal).

PROSPECTIVE COHORT STUDIES OF NNS USE AND DIABETES
==================================================

One prospective cohort study followed participants between 2000 and 2007, tracking both self-reported signs of diabetes and diet soda consumption.[@ref26] The results showed a 67% increased relative risk for type 2 diabetes in those reporting at least daily consumption of diet soda. These results were independent of baseline measures of adiposity.

A meta-analysis of prospective cohort studies evaluating NNS reported similar increased risk for diabetes among individuals who fall among the highest quartile of NNS consumption versus the lowest quartile (risk ratio \[RR\], 1.14; 95% CI, 1.05−1.25).[@ref18] The relative risk was found to increase by 3% for each additional daily serving of NNS consumed (RR, 1.03; 95% CI, 1.01−1.05).[@ref18] When compared to sugar-sweetened beverages, diet sodas have a reduced association with diabetes (population attributable fraction, 11.9%; 95% CI, 7.4%−16.5%).[@ref27]

RANDOMIZED, CONTROLLED TRIALS OF NNS USE AND DIABETES
=====================================================

Studies of type 2 diabetes must be long-term to measure disease development. Therefore, randomized, controlled trials tend to focus on effects of NNS on hormones associated with diabetes. The mechanisms affecting diabetes are shown in [Fig. 1](#F1){ref-type="fig"}. The results of studies looking at NNS effect on glucose metabolism are not yet clear. Many studies are contradictory, or simply demonstrate no obvious patterns. Adiposity may be one confounding factor, but the relationship between adiposity and diabetes has not yet been fully described.

Two meta-analyses examined fasting blood glucose. Toews et al.[@ref19] included two randomized, controlled trials with a total population of 174 and found a small reduction in glucose (−0.16 mmol/L; 95% CI, −0.26 to −0.06). A meta-analysis by Onakpoya and Heneghan[@ref28] also reported similar beneficial effects on fasting blood glucose. This meta-analysis focused solely on steviol glycosides and included six studies with a total population of 521. The results demonstrated that in randomized, controlled trials, steviol glycosides reduced fasting glucose (−0.63 mmol/L; 95% CI, −0.90 to−0.36 mmol/L).

A minority of studies have found effects of NNS on hormonal responses.[@ref29],[@ref30] Increases in glucagon-like peptide-1 (GLP-1) have been reported in multiple studies, but this response is not observed when NNS are delivered directly to the stomach.[@ref31] This suggests that the GLP-1 response is triggered by sweet taste receptors in the mouth, rather than processes in the stomach. Generally, NNS are not thought to have significant effects on hormone responses. Many studies show no difference in response against water or similar control.[@ref32][@ref33]-[@ref34] Furthermore, no response is seen when NNS are used as preloads for a meal when compared to a control.[@ref29]

SWEET TASTE RECEPTORS
=====================

Sweet taste begins in the oral cavity, when a sweet tastant binds to a sweet taste receptor. Sweet taste receptors are formed by Gprotein coupled receptors with two subunits (T1R2/T1R3).[@ref35] When sweet taste receptors have been triggered, neurotransmitters are released to the brain. Repeated exposure to intensely sweet tastes from natural sources results in adaptations that reduce sensitivity to sweetness.[@ref36] Reduced sensitivity to sweetness may alter the body's ability to gauge calorie intake through sweet taste by providing sweet perceptions without also providing nutrition. If this is the case, then chronic consumption of NNS would skew appetite regulation. Evidence exists to suggest that this may not be the case, as NNS have not reliably been shown to trigger such adaptations.[@ref37] The relationship between sweet taste, appetite, and caloric intake is poorly understood and lacks evidence.

Swithers et al.[@ref31] address this hypothesis through a series of experiments using similar methodologies with minor alterations made to each. All of these experiments focused on incorporating ad libitum consumption of alternating meals of plain food and either glucose or saccharin. Swithers' experiments varied in NNS delivery, duration, and diet accompanying the NNS, yet derived similar results. The findings show that rats consume more calories, gain more weight, and have higher resting glucose after intermittent saccharin consumption than intermittent glucose consumption. These findings have also been demonstrated for other NNS.[@ref38] The reason for the discrepancy between Swither's rodent studies and human studies has yet to be elucidated. Though likely multifaceted, the difference lies mostly in study design. If controlled, experimental human studies were to introduce a design focused on chronic exposure to NNS, results similar to rodent studies and prospective cohort studies may arise. Most controlled, experimental studies in humans fail to account for cumulative previous exposure or to follow NNS use long enough to see an adaptive effect from chronic use.

The aforementioned studies support the hypothesis that disturbances in the perception of caloric intake by NNS can lead to negative health outcomes. As of now, such research has not been done in humans. Unlike rats, humans are exposed to widely varying sources of food. Many sources of sweet taste and nutrition exist in the typical person's diet, thus bringing into question whether one source could cause similar shifts as those seen by Swithers et al.[@ref31] It is yet to be determined whether NNS could cause metabolic diseases such as obesity or diabetes in this way.

Recent studies observing sweetness responses to NNS brings such questions into further scrutiny. Some argue that NNS are not super-normal stimuli at all, and are thus unable to have a greater effect than sucrose.[@ref39] In other words, they are not a more intensely sweet stimulus than normal sugar. If this were the case, the basis of understanding for sweet taste receptor-based theories regarding NNS would be flawed.

Concepts about NNS and sweet taste receptor interactions are relatively new and unestablished. Further research is needed to fully understand the mechanisms underlying current observations, and to determine if sweet taste perception can affect metabolic disease risk in humans.

GUT MICROBIOME
==============

The human gut is host to more than 100-trillion microbial cells. This complex ecosystem plays essential roles in metabolic regulation. Through symbiotic interactions with the host, the gut microbiome can alter energy metabolism.[@ref40] Although the exact mechanisms are yet unknown, the gut microbiome is believed to be associated with metabolic disease in both humans and animals.[@ref41],[@ref42] This hypothesis is supported by studies in which feces were transplanted from obese and lean mice to germ-free mice. Despite no differences in diet or caloric intake, the mice receiving transplants from obese mice gained more weight than those receiving transplants from lean mice.[@ref43]

The link between the gut microbiome and NNS consumption has been noted since the early 1980s.[@ref44] At that time, saccharin exposure was shown to alter the balance between varieties of bacteria. Male rats that consumed saccharin for 10 days had a decrease of anaerobic gut bacteria and an increase in aerobic bacteria, demonstrating that specific microbiota could be targeted by dietary interventions. Furthermore, such evidence suggests that negative health effects associated with certain gut microbiota could result from NNS consumption. Animal research, particularly in livestock, has been particularly beneficial to our understanding of NNS effect on microbiota.[@ref45] NNS-sweetened livestock feed has been shown to improve feed efficiency, which is the amount of weight gained in ratio to amount of feed consumed.[@ref46],[@ref47] These studies demonstrate that NNS consumption can lead to disruptions in gut microbiota that encourage obesity and insulin resistance. While this may be ideal for producing quality livestock products, it is detrimental to the prevention of metabolic disease in humans.

Significant alterations in gut microbiome have been reported in rats that have consumed sucralose.[@ref48] Sucralose is associated with patterns of decreased bacterial counts and reduced bacterial diversity over time.[@ref49] Specifically, beneficial anaerobes such as bifidobacteria, lactobacilli, and *Bacteroides* suffered the greatest reductions, while negative enterobacteria seemed more resistant to sucralose. Negative alterations in gut microbiome species have also been shown for other sweeteners, such as aspartame.[@ref50]

A recent study by Suez et al.[@ref51] illustrated how glucose intolerance stemming from the gut microbiota is linked to NNS consumption. In this study, saccharin, sucralose, aspartame, sucrose, and glucose were individually provided to groups of lean and obese mice. The three NNS resulted in higher markers of glucose intolerance than sucrose or glucose, with saccharin being particularly potent. The gut microbiota responded in such a way that resembled the gut environment found in individuals with type 2 diabetes. To ensure that gut microbiota were involved in glucose intolerance, researchers gave fecal transplants from saccharin-fed mice to germ free mice. The germ-free mice than began to show signs of glucose intolerance. In all mice, antibiotic treatments reversed the glucose intolerance, adding further merit to the hypothesis that the condition is associated with gut microbiota.[@ref51] These results suggest that glucose intolerance could be induced by NNS (particularly saccharin) consumption alone.

A DISCREPANCY BETWEEN PROSPECTIVE COHORT AND RANDOMIZED, CONTROLLED STUDIES IN DIABETES AND OBESITY
===================================================================================================

NNS have long been used to restrict caloric intake and prevent or reverse obesity. Studies have been divided regarding whether NNS use can be beneficial for weight management. A closer look at this divide shows that the type of study is largely indicative of whether the results will be positive, negative, or neutral. Prospective cohort studies that observe a large sample over a long period of time tend to result in negative indications regarding weight management outcomes. However, randomized, controlled studies, which have smaller samples and better controls, most often demonstrate neutral or positive benefits for NNS use.

Similar to studies of obesity, there is stark polarization between prospective cohort and randomized, controlled studies of type 2 diabetes. Similarly, positive outcomes are found in randomized, controlled trials, while prospective cohort studies show negative outcomes ([Fig. 2](#F2){ref-type="fig"}). The reason for this difference between prospective cohort and randomized, controlled studies lies mostly in the controls. During prospective cohort studies, participants are free living, while additional variables are controlled in randomized, controlled trials. This results in comparisons between two very different scenarios.

Participants in prospective cohort studies are currently living without any interventions and are not part of a focused demographic. As a result, these data may be very skewed by unknown variables. For example, individuals whose consumer selections include diet beverages and other items sweetened with NNS tend to already be obese or to have diabetes. NNS are significantly more popular among obese individuals when compared to those who are normal-weight or underweight.[@ref6] Therefore, these studies are limited by reverse causality. Nevertheless, prospective cohort studies demonstrate how NNS may not actually be beneficial for improving weight management when individuals are no longer being monitored by researchers. This hypothesis is supported by rodent studies which have shown weight gain, glucose intolerance, or inflammation associated with NNS consumption.[@ref38],[@ref52] For these studies, reverse causality is not a risk, as external variables, such as consumer decisions based on body perceptions, do not exist in rodents.

Reversing this idea, the results of randomized, controlled trials demonstrate the potential benefits of a closely-monitored diet in combination with NNS consumption. These studies often include NNS in hypocaloric diets, while controlling for other variables.[@ref53],[@ref54] Their results show how NNS could be used as part of larger dietary modifications, if the individual is carefully monitoring the complete diet. Careful monitoring of the diet would also limit caloric overcompensation. This is related to the idea that an individual would believe that since they reduced their caloric intake with NNS, they can now replace those calories with other food. As a result, they perceive that what they are eating has less calories than it does. This may lead to individuals consuming more calories than they initially saved.[@ref55]

FURTHER RESEARCH NEEDS
======================

While the topic of NNS has attracted considerable research and commanded public opinion, much about NNS has yet to be fully understood. Multiple gaps in our understanding of the links between NNS and metabolic disease remain. At this point, we are unable to determine whether NNS consumption has beneficial or negative effects on health, particularly in the context of metabolic disease. The key need is for well controlled, long-term research projects investigating NNS effects and mechanisms. While there have been many prospective cohort studies, there is a lack of studies that examine the long-term impacts of NNS in more controlled environments. Such experiments should utilize randomization to assign participants into NNS and control groups in order to eliminate the possibility of reverse causality. It would be a novel approach to design a study that is both longitudinal and well controlled. Information regarding adaptation to chronic use of NNS would therefore be gained. This knowledge would have translational importance in informing health protocols.

In addition to being inexpensive and non-invasive, diet and exercise are two of the most potent preventative methods and ways to manage, or even reverse, the onset of diabetes and obesity.[@ref56] Physical activity improves insulin response, as well as overall cardiovascular health and other physiological functions. Moderate intensity exercise is commonly suggested for individuals, with or without presence of metabolic disease. It has favorable effects on overall health, along with controlling present disease through diverse mechanisms.[@ref57]

Despite the frequency with which diet and exercise in combination are prescribed, little research has been done to elucidate what, if any, effects result from the combination of NNS and exercise. A single study has examined such effects and shown that aspartame in conjunction with carbohydrates lowered insulin levels during exercise compared to carbohydrates alone.[@ref58] Further research is needed to investigate and understand the interactions between exercise and NNS.

The rising interest in child and infantile NNS consumption warrants further investigation. Babies are exposed to NNS consumed by their mother via breast milk, exposure that has been hypothesized to have potential clinical implications.[@ref59] It is unknown whether early exposure could lead to metabolic disease risks later in adulthood. Likewise, children exposed to NNS may be at increased risk for detriments to metabolic health. The current research lacks clarity on these matters,[@ref60] and further research is necessary to inform recommendations for NNS use among young populations.

Certain emerging sweeteners, such as stevia, have an underwhelming presence in the literature. Currently, most studies focus on aspartame and sucralose, which are the two sweeteners that make up the majority of NNS consumption.[@ref3] Stevia represents an important research focus as it is gaining popularity the quickest.[@ref61] Additionally, as a natural low-calorie sweetener, it represents a unique target. Similarly, NNS in combination, as they are typically found in a consumer setting, are less commonly utilized. Future research should consider newer sweeteners and including NNS as they are found in the marketplace.

CONCLUSION
==========

Researchers have yet to fully describe the long-term or acute effects of NNS consumption on metabolic diseases. Currently, the results of many studies appear contradictory, although this may be due to flaws in the two most commonly utilized study designs. Randomized, crossover designs are ideal for controlled studies, but fail to account for long term effects and human behavior in free-living scenarios. Conversely, prospective cohort studies show that NNS users are more likely to have metabolic disease but are biased, since individuals with metabolic disease are more likely to consume NNS in the first place. There is a need for research designed to combat these specific flaws.

More studies are also needed to provide insights into the mechanisms by which NNS may affect metabolic health, both positively and negatively. Research has yet to determine the effects of chronic NNS consumption, to see whether NNS act as a beneficial tool to combat overconsumption of carbohydrates or if NNS pose equal or greater risks as a NS.
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###### 

Non-nutritive sweeteners approved by the United States Food and Drug Administration for use in food

  Sweetener name         ADI (mg/kg/day)   Brand name                                                 Times sweeter than table sugar   Number of sweetener packets equivalent to ADI
  ---------------------- ----------------- ---------------------------------------------------------- -------------------------------- -----------------------------------------------
  Saccharin              15                Sweet and Low, Sweet Twin, Sweet\'N Low, and Necta Sweet   200--700                         45
  Aspartame              50                Nutrasweet, Equal, and Sugar Twin                          200                              75
  Acesulfame potassium   15                Sunett and Sweet One                                       200                              23
  Sucralose              5                 Splenda                                                    600                              23
  Neotame                0.3               Newtame                                                    7,000--13,000                    23
  Advantame              32.8                                                                         20,000                           4,920
  Steviol glycosides     4                 Truvia, PureVia, and Enliten                               200--400                         9
  Monk fruit extract     Not specified     Nectresse, Monk Fruit in the Raw, and PureLo               100--250                         ADI not specified

ADI, acceptable daily intake.

###### 

Meta-analyses of non-nutritive sweeteners

  Study                                                                                                    Type (number of studies included)   Variable and result
  -------------------------------------------------------------------------------------------------------- ----------------------------------- ---------------------------------------
  Wiebe et al. (2011)[@ref25]                                                                              RCT (53)                            Fasting blood glucose: ↔ (40 studies)
  Energy intake: ↓↓ (2 studies lasting \> 10 weeks)                                                                                            
  Total cholesterol: ↔ (7 studies)                                                                                                             
  Onakpoya and Heneghan (2015)[@ref28]                                                                     RCT (steviol glycosides only) (9)   Systolic BP: ↔ (7 studies)
  Diastolic BP: ↓↓ (11 studies)                                                                                                                
  Fasting blood glucose: ↓↓ (6 studies)                                                                                                        
  Total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides: ↔ (6 studies)                                       
  Toews et al. (2019)[@ref19]                                                                              RCT (21)                            BMI: ↓ (17 studies)
  Fasting blood glucose: ↓ (2 studies)                                                                                                         
  Cohort (35)                                                                                              Body weight: ↑↑ (4 studies)         
  Body weight in children: ↔ (1 study)                                                                                                         
  Azad et al. (2017)[@ref18]                                                                               RCT (7)                             BMI: ↔ (3 studies)
  Body weight: ↔ (5 studies)                                                                                                                   
  Cohort (30)                                                                                              BMI: ↑↑ (3 studies)                 
  Body weight: ↑↑ (2 studies)                                                                                                                  
  Metabolic syndrome and type 2 diabetes: ↑↑ (13 studies)                                                                                      
  Miller and Perez (2014)[@ref17]                                                                          RCT (15)                            Body weight: ↓↓ (15 studies)
  BMI: ↓↓ (6 studies)                                                                                                                          
  Fat mass: ↓↓ (6 studies)                                                                                                                     
  Waist circumference: ↓↓ (3 studies)                                                                                                          
  Cohort (9)                                                                                               Body weight: ↔ (4 studies)          
  Fat mass: ↔ (2 studies)                                                                                                                      
  BMI: ↑↑ (6 studies)                                                                                                                          

RCT, randomized controlled trials; BP, blood pressure; BMI, body mass index; ↔, no change; ↓, small decrease; ↓↓, significant decrease; ↑↑, significant increase.
